UPDATE: Pritchard Capital Partners Raises PT to $160 on Core Laboratories

Pritchard Capital Partners increases its price from $140 to $160 on Buy-rated Core Laboratories

following a strong quarter report. Pritchard Capital Partners notes, "We are even more optimistic following the CLB call. We are tweaking our Q2 EPS estimate to account for a potential increase in expenses related to the new listing. Keeping our 2012 and 2013 EPS estimates and increasing our target price to $160 up from $140. CLB continues to be one of our top picks." CLB closed at $130.48 on Wednesday.